What is the appropriate dosage of Xphozah (tenapanor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Xphozah (Tenapanor) Dosage

The FDA-approved dosage of Xphozah (tenapanor) is 30 mg orally twice daily, taken just prior to the morning and evening meals. 1

Dosing Regimen

For chronic kidney disease patients on dialysis with hyperphosphatemia:

  • Standard dose: 30 mg twice daily before the first and last meals of the day 1
  • Monitor serum phosphorus levels and adjust dosage as needed to manage gastrointestinal tolerability 1

Important timing considerations:

  • Take just prior to meals (not with or after meals) 1
  • Do NOT take right before a hemodialysis session - instead, take before the next meal following dialysis to minimize diarrhea risk 1
  • If a dose is missed, skip it and take the next dose at the regular time 1

Dose Titration in Clinical Practice

While the FDA-approved dose is 30 mg twice daily, clinical trials have demonstrated a dose-ranging approach:

  • Starting dose in some studies: 5 mg twice daily, with gradual titration up to 30 mg twice daily based on serum phosphorus levels and tolerability 2, 3
  • This stepwise approach may improve tolerability, as diarrhea (the most common adverse event) is dose-dependent 4

Critical Safety Considerations

Diarrhea is the primary dose-limiting adverse event:

  • Occurs in 43-53% of patients at the 30 mg twice daily dose 1
  • Most cases are mild-to-moderate and resolve over time or with dose reduction 1
  • Severe diarrhea occurs in approximately 5% of patients and requires treatment discontinuation 1
  • Can lead to dehydration and hyponatremia in <1% of patients 1

Contraindications:

  • Children under 6 years of age (risk of severe dehydration) 1
  • Known or suspected mechanical gastrointestinal obstruction 1

Alternative Indication: IBS-C

For irritable bowel syndrome with constipation (IBS-C), the FDA-approved dosage is 50 mg twice daily - this is a different indication and higher dose than for hyperphosphatemia 5. This dosing was established through phase 2b and phase 3 trials demonstrating moderate-certainty evidence for symptom relief 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.